-
31.发明申请公开(公告)号：US20200312642A1
公开(公告)日：2020-10-01
申请号：US16900308
申请日：2020-06-12
申请人： Metabolon, Inc.
发明人： William Lefew , David V. Foster , Rex A. Dwyer , Shelby S. Matlock , Casson Stallings , Michael Humphrey , Michael Heiser
摘要： A method, apparatus, and computer-readable storage medium for analyzing component separation/mass spectrometer data for a sample having known characteristic includes analyzing reference ion data for a relationship between ion mass, retention time, and intensity. The analyzed data is added to a repository, wherein each ion therein has an intensity maxima within a characteristic retention time range for a characteristic ion mass. If the reference ion is in the repository, the range is modified according to the characteristic retention time of the reference ion intensity maxima. Based on the known characteristic, an ion expected in the sample is selected from the repository, and sample data is compared to data for the ion selected from the repository to determine whether the ion is present in the sample. The range in the repository is then modified according to the characteristic retention time of the intensity maxima for the ion present in the sample.
-
32.发明申请公开(公告)号：US20200158702A1
公开(公告)日：2020-05-21
申请号：US16604357
申请日：2018-04-16
申请人： Metabolon, Inc.
IPC分类号： G01N30/72 , H01J49/16 , G01N27/62 , G01N33/493 , G01N33/68
摘要： A method for determining in a sample, by mass spectrometry, the presence, absence, or amount of one or more analytes is described herein. The run time is less than six minutes. The method includes subjecting the sample to an ionization source under conditions suitable to produce one or more ions detectable by mass spectrometry from each of the one or more analytes, wherein the one or more analytes are derivatized prior to ionization; measuring, in a single injection, by mass spectrometry, the amount of the one or more ions from each of the one or more analytes; and using the measured amount of the one or more ions to determine the amount of each of the one or more analytes in the sample.
-
公开(公告)号：US10573406B2
公开(公告)日：2020-02-25
申请号：US14856184
申请日：2015-09-16
申请人： METABOLON, INC.
摘要： A method is provided for analyzing metabolite data in a sample, comprising analyzing a sample to determine a first number of metabolites, and amount of each metabolite, included in the sample, and a second number of the first number of metabolites that are regulated. Biochemical pathways are determined, each having a third number of the first number of metabolites that are included in the sample and in the determined biochemical pathway. For each of the determined biochemical pathways having the third number of metabolites, a fourth number of the second number of metabolites that are included in the sample and in the determined biochemical pathway that are regulated metabolites is determined. Each of the third number of metabolites within one of the determined biochemical pathways is displayed and distinguished by the amount of each corresponding metabolite included in the sample. An associated apparatus and computer program product are also provided.
-
公开(公告)号：US10175233B2
公开(公告)日：2019-01-08
申请号：US14975988
申请日：2015-12-21
申请人： Metabolon, Inc.
发明人： Yun Fu Hu , Costel Chirila , Danny Alexander , Michael Milburn , Matthew W. Mitchell , Walter Gall , Kay A. Lawton
IPC分类号： G01N33/68 , G01N33/53 , G01N33/483 , G01N33/50 , G01N33/487
摘要： Biomarkers relating to cardiovascular disease, including atherosclerosis and cardiomyopathy, are provided, as well as methods for using such biomarkers as biomarkers for cardiovascular disease. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for cardiovascular disease, including atherosclerosis and cardiomyopathy.
-
公开(公告)号：US20180203021A1
公开(公告)日：2018-07-19
申请号：US15872373
申请日：2018-01-16
申请人： Metabolon, Inc.
CPC分类号： G01N33/6893 , G01N33/5308 , G01N2333/46 , G01N2800/042 , G01N2800/32 , G01N2800/324 , G01N2800/50 , G01N2800/52 , G01N2800/60 , G16H50/30
摘要： Biomarkers relating to insulin resistance and insulin resistance-related disorders are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease. In addition, methods for monitoring the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease.
-
公开(公告)号：US09977034B2
公开(公告)日：2018-05-22
申请号：US14843356
申请日：2015-09-02
发明人： Bruce J. McCreedy , Alvin Berger , YunFu Hu , Satish C. Kalhan
CPC分类号： G01N33/6893 , G01N2500/00 , G01N2570/00 , G01N2800/085 , G01N2800/52 , G01N2800/56 , G01N2800/60 , H01J49/0027 , Y10T436/143333 , Y10T436/163333 , Y10T436/200833
摘要： The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.
-
公开(公告)号：US20180031541A1
公开(公告)日：2018-02-01
申请号：US15548854
申请日：2016-02-04
申请人： Metabolon, Inc.
发明人： Luke Miller , Klaus Peter Adam , Michael V. Milburn , Jeffery E. Cobb , Anne M. Evans , Qibo Zhang
IPC分类号： G01N33/50 , C07K16/44 , C07D307/33
CPC分类号： G01N33/50 , A61K31/137 , A61K31/155 , A61K31/341 , A61K31/4439 , A61K31/485 , A61K31/7048 , C07D307/33 , C07K16/44 , C07K2317/56 , C07K2319/00 , G01N33/5008 , G01N33/507 , G01N33/6893 , G01N2800/042 , G01N2800/52
摘要： The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.
-
38.发明申请Biomarkers Related to Insulin Resistance Progression and Methods Using the Same 有权与胰岛素抵抗相关的生物标志物进展及其使用方法公开(公告)号：US20150362510A1
公开(公告)日：2015-12-17
申请号：US14763962
申请日：2014-01-16
申请人： METABOLON, INC.
CPC分类号： G01N33/6893 , G01N33/5308 , G01N2333/46 , G01N2800/042 , G01N2800/32 , G01N2800/324 , G01N2800/50 , G01N2800/52 , G01N2800/60 , G06F19/00 , G16H50/30
摘要： Biomarkers relating to insulin resistance and insulin resistance-related disorders are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease. In addition, methods for monitoring the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease.
摘要翻译： 提供了与胰岛素抵抗和胰岛素抵抗相关疾病相关的生物标志物，以及使用这些生物标志物作为胰岛素抵抗，血糖异常，2型糖尿病和心血管疾病的生物标志物的方法。 此外，还提供了用于监测受试者的各种疾病或病症的方法。 还提供了小分子实体的套件作为胰岛素抵抗，血糖异常，2型糖尿病和心血管疾病的生物标志物。
-
公开(公告)号：US12050228B2
公开(公告)日：2024-07-30
申请号：US17097491
申请日：2020-11-13
申请人： Metabolon, Inc.
发明人： Adam D. Kennedy , Matthew W. Mitchell , Meredith V. Brown , Kay A. Lawton , Shaun Lonergan , Jacob Edward Wulff
IPC分类号： G01N35/00 , G01N33/48 , G01N33/49 , G01N33/50 , G01N33/53 , G01N33/66 , G01N33/68 , G01N33/92 , G16B40/10 , G16B50/00 , G16B50/10 , G16B50/30 , G16B99/00
CPC分类号： G01N35/00613 , G01N33/48 , G01N33/492 , G01N33/50 , G01N33/5308 , G01N33/66 , G01N33/68 , G01N33/92 , G16B40/10 , G16B50/00 , G16B50/10 , G16B50/30 , G16B99/00 , G01N2560/00 , G01N2570/00
摘要： A method of assessing the quality of a biological sample while maintaining the viability of the biological sample for intended use analysis is described herein. The method includes analyzing a biological sample obtained from a subject for an intended use, assessing the quality of the biological sample using one or more biomarkers of sample quality, and simultaneously performing intended use analysis on the same sample. Assessing the quality of the sample can include assessing compliance with sample handling protocols and assessing subject compliance.
-
公开(公告)号：US20220034865A1
公开(公告)日：2022-02-03
申请号：US17345365
申请日：2021-06-11
申请人： Metabolon, Inc.
发明人： Luke Miller , Klaus Peter Adam , Michael V. Milburn , Jeffery E. Cobb , Anne M. Evans , Qibo Zhang
IPC分类号： G01N33/50 , G01N33/68 , A61K31/485 , A61K31/155 , A61K31/4439 , A61K31/7048 , A61K31/137 , A61K31/341 , C07D307/33 , C07K16/44
摘要： The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.
-
-
-
-
-
-
-
-
-
搜索结果
52 条记录 (耗时 0.036 秒)
